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FIGHTING FLU
(ill is influenza vaccine safe in HIV-infected persons?; and
(iiil is influenza vaccine effective in HIV-infected
persons7
IS HIV INFECTION A SPECIAL INDICATION FOR
ANNUAL INFLUENZA IMMUNISATION?
Definitive, quantitative epidemiological data on the risk
of influenza complications in HIV-infected persons are
still not available. However, small-scale studies have
shown more severe and prolonged influenza disease in
HIV-infected persons."'" Additional factors which would
also need to be taken into account when considering
whether HIV infection constitutes a special indication
for influenza immunisationinclude the following:
(i) uncomplicated influenza illness may involve consid-
erable expense and inconvenience to eliminate a
diagnosis of Pneumocystis disease in HIV-infected
patients presenting with an acute febrile illness;
(iil increased influenza virus shedding has been asso-
ciated with depressed immunity;" and
(iii) the antigenic stimulation of influenza virus infec-
tion itself is associated with an increased plasma
viral load," one of the concerns raised with influ-
enza vaccine (see below).
INFLUENZA IMMUNISATION IN
HIV-INFECTED PERSONS
Influenza vaccines are widely used throughout the world.
Some 80 - 85 million doses are produced annually for
distribution in the USA alone' where coverage for the
major risk group, persons over 65 years of age, was 630/0
in 1997' (surpassing the 6O'lb vaccine coverage goal for
the country's Healthy People 2000 Project). The clinical
effectiveness as well as the cost effectiveness of influ-
enza vaccines have been clearly established in a number
of studies in many parts of the world.'" Influenza
vaccination has also been demonstrated to reduce
hospitalisation significantly in elderly high-risk persons.~"
In South Africa, influenza immunisation has similarly
been demonstrated to be cost effective" and utilisation
of vaccine in this country has increased markedly over
the past few years, reaching over 2 million doses admin-
istered in 2000. Annual influenza immunisation is sound
preventive medicine generally, and in particular is
mandated for persons at risk for complications of
influenza."
With regard to influenza immunisation of HIV-infected
persons, three issues need to be considered:
(i) are HIV-infected persons at special risk for influenza
complications and is annual immunisation specifically
advocated for them?;
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The Advisory Committee on Immunisation Practices
(ACIP) of the USA has recognised persons infected with
HIV as a specific targer group for influenza immunisation
because of the increased risk of complications.'
IS INFLUENZA VACCINE SAFE IN
HIV-INFECTED PERSONS?
In uenza vaccines presemly in use are inactive subunit or
split-product vaccines and therefore pose no risk of
disease directly associated with the vaccine virus, as is
the case with he use of live attenuated viral vaccines
in immunosuppressed persons. The main concern about
adminis ering influenza vaccine to HIV-infected persons
has been the observed effect on plasma viral load
following administration of influenza and other vaccines.
In 1992, a short letter from Oavid Ho in the Lancer'
drew attention to the increase in infectious HIV-l in
plasma and peripheral blood mononuclear cells following
influenza infection as well as influenza vaccination.
The rise in viraemia was, however, transient and levels
returned to baseline by 2 - 3 weeks. Ho further cautioned
in the letter that the findings 'should not be used to make
clinical decisions about influenza vaccination in HIV-l
infected persons: A number of publications followed
which demonstrated the expected rise in plasma HIV-l
RNA levels following antigenic stimulation and Iympho-
cyte proliferation induced by influenza and other
vaccines:o-,~ It was also noted that influenza vaccine-
induced stimulation of HIV replication was more likely
to occur in individuals with higher C04 cell counts, i.e.
those individuals who would, in fact, be the most likely
to develop an immune response and benefit from the
vaccine. However, other subsequem s udies have not
shown significant increases in viraemia following influ-
enza vaccine administration,"'" or alterna ively showed
that the rise in viraemia was not only transient and rarely
significam but was also not associared with any clinical
events."';: Where transient increases in HIV-l RNA levels
have occurred following vaccination, they have not been
'allowed by any sustained deterioration in CD4 Iympho-
cyte cell counts or progression of disease."
IS INFLUENZA VACONE EFFECTIVE IN
HIV-INFECTED INDMDUALS?
Resistance to influenza infection is mediated by humoral
immunoglobulin G (IgGl antibodies in plasma and sec-
retory immunoglobulin A (IgA) in respiratory secretions,
while recovery from infection, as demonstrated in animal
models, is mediated by specific CTL (C08 cytotoxic Iym-
phocyte) activity. Both immune responses are governed
by functionally intact C04 Iymphocytes. It was therefore
not surprising that with the progressive decline of C04
Iymphocyte coums there is a corresponding decline in
immune response to influenza vaccine. Individuals with
CD4 coums less rhan 200/ml show a poor immune resp-
onse to influenza virus infection or influenza vacci-
nation." An additional administration of a second dose,
however, had no beneficial effect and these non-
responding vaccine recipients remained unprotected
after a second dose." Asymptoma ically infected persons
or those with persistent generalised lymphadenopathy




HIV infection is generally regarded as a specific risk,
and it is recommended hat affec ed individuals receive
annual influenza immunisation.u, It is specifically recom-
mended under the following conditions:"
(i) HIV-infected persons with symptoms and/or C04
cell counts between 200 and 5OO/ml;
(iil HIV-infected persons with another condition placing
them in a higher risk category according to general
influenza recommendations;u, and
(iii) contacts of HIV-infected patients such as health
care personnel and household members.
It is not recommended for HIV-infected persons with
CD4 cell counts below 200lml as they are unlikely to
mount an adequate immune response. These individuals
should be protected with chemoprophylactic agents such
as amantadine (Symmetrel).
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